Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of <sup>14</sup>C-plitidepsin.

导出原文传递

翻译打印收藏纠错

作者： L,van Andel ^[1] ; H,Rosing ^[2] ; M M,Tibben ^[3] ; L,Lucas ^[3] ; R,Lubomirov ^[3] ; P,Avilés ^[4] ; A,Francesch ^[4] ; S,Fudio ^[4] ; A,Gebretensae ^[4] ; M J X,Hillebrand ^[3] ; J H M,Schellens ^[3] ; J H,Beijnen ^[5]

作者单位： Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands. l.v.andel@nki.nl. ^[1] Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. l.v.andel@nki.nl. ^[2] Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands. ^[3] Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain. ^[4] Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[5] Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[6] Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. ^[7]

关键词 ADME Aplidin LC-MS/MS Metabolite profiling Plitidepsin Total radioactivity